- Poster presentation
- Open Access
Why does apical hypertrophic cardiomyopathy have a favorable outcome than non-apical types?: Cardiac magnetic resonance and echocardiographic findings from 350 patients with hypertrophic cardiomyopathy
© Kim et al.; licensee BioMed Central Ltd. 2014
Published: 16 January 2014
Apical HCM tends to have a favorable outcome compared to other types. The presence and extent of late gadolinium enhancement (LGE), reflecting myocardial fibrosis, is closely correlated with increased cardiac mortality and strongly associated with surrogates of arrhythmia and subsequent sudden cardiac death. This study sough to investigate the difference in cardiac magnetic resonance (CMR) and echocardiographic and clinical manifestations between apical hypertrophic cardiomyopathy (HCM) and non-apical HCM.
A total of 350 consecutive patients diagnosed with HCM (mean age 54 ± 12, 278 males) underwent CMR and echocardiography. Clinical characteristics including risk factors for sudden cardiac death were collected. Eighty-five patients were classified as apical type. On CMR, left ventricle (LV) volumetric parameters were measured, and the amount of LGE was calculated with gray-scale thresholds of 6 SD above the mean signal intensity for normal remote myocardium and also expressed as a ratio against total LV volume. Echocardiographic evaluations included left atrial volume index (LAVI), mitral inflow pattern, tissue Doppler of mitral annulus and LV dimension.
Patients with apical HCM were less likely to present with history of syncope (2.4% vs. 10.2%, p = 0.02) and have family history of sudden cardiac death than those with non-apical HCM (5.9% vs. 15.8%, p = 0.02). Functional class was also more favorable in apical HCM (frequency of NYHA class I; 89.4% vs. 66.8%, p < 0.001). CMR volumetric parameters were not different between the two groups except LV mass index (71.7 ± 17.3 vs. 92.0 ± 34.1, p < 0.001). LGE was less frequently detected (87.1% vs. 93.9%, p = 0.04), and the amount of LGE was significantly smaller in apical HCM (7.0 ± 6.0% vs. 14.6 ± 10.5%, p < 0.001). The E/e level and LAVI were also lower in apical HCM patients (E/e; 10.1 ± 3.3 vs. 13.6 ± 5.7, p < 0.001 and LAVI; 40.4 ± 20.8 vs. 45.9 ± 16.9, p < 0.001).
Apical hypertrophy shows relatively small burden of myocardial fibrosis and less severe diastolic dysfunction, and subsequently more favorable clinical manifestations in comparison with other HCMs. This may be one explanation of why most patients with apical HCM show a benign course of disease compared to non-apical HCM.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.